Location History:
- Kiyose, JP (1995 - 1996)
- Tokyo, JP (1985 - 2012)
Company Filing History:
Years Active: 1985-2012
Title: Kimitomo Yoshioka: Innovator in Immunosuppressive Agents
Introduction
Kimitomo Yoshioka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of immunology, particularly in the development of novel immunosuppressive agents. With a total of 9 patents to his name, Yoshioka's work is recognized for its potential impact on treating immune diseases.
Latest Patents
Yoshioka's latest patents include innovative methods for creating immunosuppressive and anti-tumor agents that utilize heterocyclic compounds as active ingredients. One of his notable inventions describes a method for administering a therapeutically effective amount of a heterocyclic compound to mammals suffering from immune diseases. This method is detailed in his patent, which outlines the general formula for the compounds involved. Additionally, he has disclosed a novel heterocyclic compound represented by a specific formula, further expanding the possibilities for pharmaceutical applications.
Career Highlights
Kimitomo Yoshioka is associated with Zenyaku Kogyo Kabushiki Kaisha, where he continues to advance his research and development efforts. His work has garnered attention in the scientific community, particularly for its innovative approaches to treating complex health issues related to the immune system.
Collaborations
Yoshioka collaborates with esteemed colleagues such as Hiroaki Yamazaki and Muneaki Takase. Their combined expertise contributes to the advancement of research in immunosuppressive therapies and enhances the potential for groundbreaking discoveries in the field.
Conclusion
Kimitomo Yoshioka's contributions to immunology through his patents and collaborations highlight his role as a key innovator in the development of new therapeutic agents. His work continues to pave the way for advancements in treating immune diseases, showcasing the importance of innovation in healthcare.